A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Therapeutic Use
  • Acronyms CIBS
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
    • 21 Oct 2014 As per the media release issued in October 2014, the company has successfully completed an end-of-phase 2 meeting with the FDA for this trial.
    • 21 Oct 2014 Results published in the Synergy Pharmaceutical Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top